&w=3840&q=100)
Poly Medicure Q4 results: Profit rises 34% on strong exports, new divisions
Delhi-based medical device manufacturer Poly Medicure on Wednesday announced a 34 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) for the March quarter of financial year 2024–25 (Q4FY25), driven by strong export revenue and the commercialisation of its new cardiology and critical care divisions.
The company's PAT for the quarter was recorded at Rs 91.8 crore, up from Rs 68.4 crore in the same period last year. Its revenue from operations rose to Rs 440.8 crore in Q4FY25, a 16.6 per cent Y-o-Y rise from Rs 378.1 crore reported in Q4FY24.
The company stated that its export revenue for the March quarter increased by 14 per cent year-on-year, driven by continued strong performance in key international markets.
Exports formed around 67 per cent of the company's revenue mix—double that of the domestic market, which accounted for 32 per cent of overall revenue in Q4.
Commenting on the performance, Himanshu Baid, managing director, Poly Medicure, said that while ongoing geopolitical conditions and uncertainty created by US-imposed tariffs may create short-term pressure on demand in certain export markets, India's Medtech sector is well positioned to benefit in the long term as global customers look to create alternate supply chains.
At the operating level, Poly Medicure's earnings before interest, tax, depreciation, and amortisation (EBITDA) rose to Rs 119.5 crore, with an EBITDA margin of 27.1 per cent in the March quarter, compared to Rs 96.5 crore and 25.5 per cent, respectively, in the same period last financial year.
Baid added that the company's margins have continued to expand at a higher scale of operations, giving it the confidence to continue investing capital in expanding manufacturing capacities.
The company currently has 12 manufacturing facilities, with three more under construction in India. It has a portfolio of over 200 medical devices across 12 medical therapies, including infusion therapy, vascular access, dialysis and renal care, among others.
On Wednesday, Poly Medicure's shares rose by 2.06 per cent, closing at Rs 2,835.65 apiece on the Bombay Stock Exchange (BSE).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
25 minutes ago
- Mint
UAE's Aqua 1 invests $100 million in Trump-linked crypto venture, amid outcry of influence peddling
Aqua 1 Foundation, a UAE-based Web3 investment fund, announced today a $100 million purchase of governance tokens in World Liberty Financial (WLF), solidifying its position as the largest individual investor in the controversial crypto venture closely tied to the Trump family. The deal marks the second major Middle Eastern investment in WLF within months, raising fresh questions about foreign influence and conflicts of interest surrounding the decentralized finance platform. The investment grants Aqua 1 significant voting rights over WLF's future development. According to a joint statement, the capital will accelerate WLF's plans to build blockchain-powered financial applications, including expanding its USD1 stablecoin and developing platforms for tokenizing traditional assets like real estate or commodities. The partnership also includes plans to co-develop "BlockRock," an institutional real-world asset (RWA) tokenization platform, and support the launch of Aqua 1's "Aqua Fund," a UAE-domiciled digital economy investment vehicle backed by regional stakeholders. "Aligning with Aqua 1 validates our blueprint for global financial innovation," said WLF co-founder Zak Folkman. 'We have a joint mission to bring digital assets to the masses and strengthen our nation's standing as a champion and leader of cryptocurrency.' Dave Lee, Aqua 1's founding partner, emphasized WLF's USD1 ecosystem represents a "trillion-dollar structural pivot opportunity" merging traditional finance with decentralized technology. This investment shines another spotlight on WLF's origins and ownership structure, which has drawn intense scrutiny since its launch: WLF was founded in 2024 and is primarily owned by DT Marks DEFI LLC, an entity controlled by Donald Trump and his family, holding approximately 60% (recently reduced from 75%). The Trump family business entity is entitled to 75% of all net revenues from WLF token sales. Eric Trump and Donald Trump Jr. are actively involved in management, while Barron Trump is listed as the project's "DeFi visionary." Initial co-founders Zachary Folkman and Chase Herro handle day-to-day operations. The Aqua 1 investment, following closely on the Abu Dhabi MGX deal, intensifies concerns among government ethics experts and critics of the Trump administration. They argue that these substantial foreign investments, particularly from nations with sovereign wealth funds and strategic interests, into a company enriching the sitting President's family create significant potential for influence peddling and conflicts of interest. The administration and WLF maintain there are no conflicts, pointing to Trump's assets being in a trust managed by his children.
Deccan Herald
36 minutes ago
- Deccan Herald
Morgan Stanley, Citigroup, 6 others buy 1.6% stake in Delhivery for Rs 461 cr
The entities picked up over 1.19 crore equity shares or 1.6 per cent stake in the company at an average price of Rs 387, taking the combined value to Rs 461 crore.
Indian Express
36 minutes ago
- Indian Express
Another HC judges recuses from hearing HDFC Bank CEO's plea against bribery charge
Yet another judge of the Bombay High Court on Thursday recused himself from hearing plea by HDFC Bank Managing Director and CEO Sashidhar Jagdishan challenging the FIR filed against him on a complaint by Lilavati Kirtilal Mehta Medical Trust (LKMM Trust), which oversees the Lilavati Hospital in Bandra (West), a prominent healthcare institution in Mumbai. The Trust, through its authorised representative and Trustee Prashant Kishor Mehta had alleged that Jagdishan had accepted a bribe of Rs 2.05 crore to help a group consisting of one Chetan Mehta and other erstwhile trustees to retain alleged illegal control over the trust. A bench of Justices Mahesh S Sonak and Jitendra S Jain noted that when the plea was mentioned for circulation before it on Monday, Justice Jain had disclosed that he has shares in HDFC Bank. When the matter was called out on Thursday, June 26 the lawyer representing complainant and respondent Prashant Mehta expressed his inability to consent to this bench taking up the said matter. Senior advocate Amit Desai for Jagdishan on the other hand said that the petitioner had no objection whatsoever in the present bench taking up the matter. He argued that merely holding shares in publicly listed companies should not by itself be the ground for recusal as several judges have shares of such companies. 'However, considering submissions made on behalf of respondent Prashant Mehta, we direct that the matter may not be placed before a bench of which Justice Jain is a party,' the HC order stated. Earlier, on June 18, when the matter came up for hearing before a bench of Justices Ajey S Gadkari and Rajesh S Patil, Justice Patil recused himself from hearing the matter. Thereafter, it was mentioned before a division bench led by Justice Sarang V Kotwal, as the alternate bench led by Justice Ravindra V Ghuge was not available till June 27. Justice Kotwal too had recused himself from hearing the matter, noting that he had earlier represented one of the trustees. The HC administration had assigned a bench of Justices Sonak and Jain to hear the matter. Justice Jain also recused himself from hearing other pleas by Keki Elavia, Venkatu Srinivasan and Kotak Mahindra group backed M/s Phoenix ARC Private Ltd challenging another FIR alleging embezzlement of trust funds to the tune of Rs 2.25 crore. The magistrate court in Bandra on May 29 had directed the Bandra police to register offences punishable under sections 406, 409 (criminal breach of trust) and 420 (cheating) of the Indian Penal Code (IPC). The magistrate had ordered the probe on the basis of a complaint by Prashant Mehta. Two days later, the Bandra police registered the FIR against Jagdishan and six others who were erstwhile trustees. However, Jagdishan claimed that the FIR was a 'retaliatory' move due to recovery proceedings initiated against Splendour Gems Limited, a company owned by the complainant's father. He said that the complainant was using the 'facade' of the Trust to seek action against the petitioner. The pleas by Jagdishan and others will now be heard in due course after the high court administration assigns another bench to hear the same.
